People who had a prior heart attack who were given 40 infusions of EDTA chelation therapy compared to those given a placebo were 18% less likely to die from any cause, have a heart attack, have a stroke, have coronary revascularization, or hospitalization for angina over the next 5 years.

A subset of people who were Type 2 diabetics had a 41% lower risk of these events happening.

EDTA chelation helps to remove heavy metals such as lead and cadmium.

“[A] body of epidemiological data showing that accumulation of biologically active metals, such as lead and cadmium, is an important risk factor for cardiovascular disease,” the authors of the paper note.

Read the entire article | Email this article

Type 2 diabetics with a prior heart attack who were given 40 infusions of EDTA chelation therapy compared to those given a placebo had a

• 43 percent reduction in death from any cause over 1-5 years
• 41 percent overall reduction in the risk of any cardiovascular event over 1-5 years
• 40 percent reduction in the risk of death from heart disease, nonfatal stroke, or nonfatal heart attack during a 1-5 year follow-up
• 52 percent reduction in recurrent heart attacks over 1-5 years

according to a study called the Trial to Assess Chelation Therapy (TACT) that was sponsored by the National Center for Complementary and Integrative Health and the National Heart, Lung, and Blood Institute at the U.S. National Institutes of Health which was the first large-scale, multicenter clinical trial on chelation therapy in people who have had heart attacks.

EDTA chelation only benefited diabetics

EDTA chelation only benefited diabetics; it did not benefit non-diabetics.

Read the entire article | Email this article

"EDTA chelation does retard or reverse atherosclerosis with improvements in edema, wound healing and in walking distance before pain," writes Joel M. Kauffman, PhD, the author of Malignant Medical Myths: Why Medical Treatment Causes 200,000 Deaths in the USA each Year, and How to Protect Yourself.

"This chapter [in my book] also showed the first example that mainstream medicine does not 'fight fair' in debunking alternative treatments any more than in promoting mainstream treatments," Kauffman notes. Read the entire article | Email this article